ES2615238T3 - Derivados de tetrahidroquinolinas como inhibidores de bromodominio - Google Patents
Derivados de tetrahidroquinolinas como inhibidores de bromodominio Download PDFInfo
- Publication number
- ES2615238T3 ES2615238T3 ES12718620.3T ES12718620T ES2615238T3 ES 2615238 T3 ES2615238 T3 ES 2615238T3 ES 12718620 T ES12718620 T ES 12718620T ES 2615238 T3 ES2615238 T3 ES 2615238T3
- Authority
- ES
- Spain
- Prior art keywords
- mmol
- methyl
- acetyl
- amino
- tetrahydroquinolin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201106750 | 2011-04-21 | ||
| GBGB1106750.1A GB201106750D0 (en) | 2011-04-21 | 2011-04-21 | Novel compounds |
| PCT/EP2012/057113 WO2012143415A1 (en) | 2011-04-21 | 2012-04-19 | Tetrahydroquinoline derivatives useful as bromodomain inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2615238T3 true ES2615238T3 (es) | 2017-06-06 |
Family
ID=44147342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12718620.3T Active ES2615238T3 (es) | 2011-04-21 | 2012-04-19 | Derivados de tetrahidroquinolinas como inhibidores de bromodominio |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8993554B2 (enExample) |
| EP (2) | EP3168213B1 (enExample) |
| JP (1) | JP5905075B2 (enExample) |
| ES (1) | ES2615238T3 (enExample) |
| GB (1) | GB201106750D0 (enExample) |
| WO (1) | WO2012143415A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201106743D0 (en) * | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
| GB201107325D0 (en) | 2011-05-04 | 2011-06-15 | Glaxosmithkline Llc | Novel compounds |
| WO2014080291A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Biaryl derivatives as bromodomain inhibitors |
| US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
| US9271978B2 (en) | 2012-12-21 | 2016-03-01 | Zenith Epigenetics Corp. | Heterocyclic compounds as bromodomain inhibitors |
| MX2015012005A (es) | 2013-03-11 | 2016-04-04 | Abbvie Inc | Inhibidores de bromodominio. |
| WO2014164780A1 (en) | 2013-03-11 | 2014-10-09 | Abbvie Inc. | Fused tetracyclic bromodomain inhibitors |
| PE20151596A1 (es) | 2013-03-14 | 2015-11-24 | Glaxosmithkline Intellectual Property N 2 Ltd | Derivados de 1-acil-4-amino-1,2,3,4-tetrahidroquinolina 2,3-disustituidos y su uso como inhibidores del bromodominio |
| CA2903881C (en) | 2013-03-15 | 2021-05-18 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
| SG11201510409QA (en) | 2013-06-21 | 2016-01-28 | Zenith Epigenetics Corp | Novel bicyclic bromodomain inhibitors |
| CA2915622C (en) | 2013-06-21 | 2020-08-18 | Zenith Epigenetics Corp. | Novel substituted bicyclic compounds as bromodomain inhibitors |
| US9290514B2 (en) | 2013-07-08 | 2016-03-22 | Incyte Holdings Corporation | Tricyclic heterocycles as BET protein inhibitors |
| US9855271B2 (en) | 2013-07-31 | 2018-01-02 | Zenith Epigenetics Ltd. | Quinazolinones as bromodomain inhibitors |
| CN106029076B (zh) | 2013-11-18 | 2019-06-07 | 福马疗法公司 | 作为bet溴域抑制剂的苯并哌嗪组合物 |
| ES2860695T3 (es) * | 2013-11-18 | 2021-10-05 | Forma Therapeutics Inc | Composiciones de tetrahidroquinolina como inhibidores de bromodominio BET |
| WO2015081203A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| WO2015081189A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| WO2015095492A1 (en) | 2013-12-19 | 2015-06-25 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
| US9142676B2 (en) | 2013-12-30 | 2015-09-22 | Taiwan Semiconductor Manufacturing Company, Ltd. | Semiconductor liner of semiconductor device |
| LT3092227T (lt) * | 2014-01-09 | 2018-08-10 | Orion Corporation | Bicikliniai heterocikliniai dariniai kaip bromodomeno inhibitoriai |
| DK3674302T3 (da) | 2014-04-23 | 2023-04-03 | Incyte Holdings Corp | 1h-pyrrolo[2,3-c]pyridin-7(6h)-oner og pyrazolo[3,4-c]pyridin-7(6h)-oner som inhibitorer af bet-proteiner |
| CN106573915B (zh) * | 2014-08-01 | 2020-12-25 | 纽韦卢森公司 | 针对布罗莫结构域有活性的化合物 |
| PT3191476T (pt) | 2014-09-12 | 2019-01-17 | Glaxosmithkline Ip No 2 Ltd | Derivados de tetra-hidroquinolina como inibidores de bromodomínio |
| EP3194406B8 (en) | 2014-09-15 | 2021-03-31 | Incyte Corporation | Tricyclic heterocycles for use as bet protein inhibitors |
| US10179125B2 (en) | 2014-12-01 | 2019-01-15 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
| EP3227281A4 (en) | 2014-12-01 | 2018-05-30 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
| HK1245248B (en) | 2014-12-11 | 2020-05-15 | 恒翼生物医药(上海)股份有限公司 | Substituted heterocycles as bromodomain inhibitors |
| HK1245247A1 (zh) | 2014-12-17 | 2018-08-24 | 恒翼生物医药科技(上海)有限公司 | 溴结构域的抑制剂 |
| GB201504694D0 (en) | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Covalent conjugates |
| WO2016203335A1 (en) | 2015-06-18 | 2016-12-22 | Pfizer Inc. | Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors |
| AR106520A1 (es) | 2015-10-29 | 2018-01-24 | Incyte Corp | Forma sólida amorfa de un inhibidor de proteína bet |
| CA3220957A1 (en) | 2016-06-20 | 2017-12-28 | Incyte Corporation | Crystalline solid forms of a bet inhibitor |
| EP3490552B1 (en) | 2016-07-26 | 2022-11-23 | University of Southern California | Selective bromodomain inhibition of fungal bdf1 |
| US11028051B2 (en) | 2016-12-13 | 2021-06-08 | St. Jude Children's Research Hospital | Tetrahydroquinoline-based bromodomain inhibitors |
| US11629152B2 (en) * | 2018-03-30 | 2023-04-18 | Kyowa Kirin Co., Ltd. | Compound with anticancer activity |
| KR20250107972A (ko) | 2018-05-04 | 2025-07-14 | 레미디 플랜, 인크. | 암 줄기 세포를 표적화하는 암 치료 |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| UY39276A (es) | 2020-06-19 | 2022-01-31 | Bayer Ag | Uso de compuestos de 1,3,4–oxadiazol–2–ilpirimidina para controlar microorganismos fitopatógenos, métodos de uso y composiciones. |
| WO2022129190A1 (en) | 2020-12-18 | 2022-06-23 | Bayer Aktiengesellschaft | (hetero)aryl substituted 1,2,4-oxadiazoles as fungicides |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| PL1699512T3 (pl) | 2003-11-03 | 2012-11-30 | Glaxo Group Ltd | Urządzenie do dozowania płynów |
| JP2008156311A (ja) | 2006-12-26 | 2008-07-10 | Institute Of Physical & Chemical Research | Ｂｒｄ２ブロモドメイン結合剤 |
| CA2710740C (en) | 2007-12-28 | 2016-07-19 | Shinji Miyoshi | Thienotriazolodiazepine compound as antitumor agent |
| WO2010018874A1 (en) * | 2008-08-12 | 2010-02-18 | Takeda Pharmaceutical Company Limited | Amide compound |
| US20100113514A1 (en) * | 2008-10-30 | 2010-05-06 | Gilead Palo Alto, Inc. | Fused heterocyclic compounds as ion channel modulators |
| WO2010111626A2 (en) * | 2009-03-27 | 2010-09-30 | Takeda Pharmaceutical Company Limited | Poly (adp-ribose) polymerase (parp) inhibitors |
| GB0919431D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| ES2539964T3 (es) * | 2009-11-05 | 2015-07-07 | Glaxosmithkline Llc | Procedimiento novedoso |
| GB0919432D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
| GB0919434D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
-
2011
- 2011-04-21 GB GBGB1106750.1A patent/GB201106750D0/en not_active Ceased
-
2012
- 2012-04-19 ES ES12718620.3T patent/ES2615238T3/es active Active
- 2012-04-19 WO PCT/EP2012/057113 patent/WO2012143415A1/en not_active Ceased
- 2012-04-19 EP EP16197070.2A patent/EP3168213B1/en not_active Not-in-force
- 2012-04-19 EP EP12718620.3A patent/EP2699551B1/en not_active Not-in-force
- 2012-04-19 US US14/111,625 patent/US8993554B2/en not_active Expired - Fee Related
- 2012-04-19 JP JP2014505612A patent/JP5905075B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2699551A1 (en) | 2014-02-26 |
| US8993554B2 (en) | 2015-03-31 |
| US20140031336A1 (en) | 2014-01-30 |
| JP5905075B2 (ja) | 2016-04-20 |
| GB201106750D0 (en) | 2011-06-01 |
| JP2014511892A (ja) | 2014-05-19 |
| WO2012143415A1 (en) | 2012-10-26 |
| EP3168213B1 (en) | 2018-08-01 |
| EP3168213A1 (en) | 2017-05-17 |
| EP2699551B1 (en) | 2016-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2615238T3 (es) | Derivados de tetrahidroquinolinas como inhibidores de bromodominio | |
| ES2544302T3 (es) | Derivados de tetrahidroquinolina útiles como inhibidores de bromodominio | |
| ES2589801T3 (es) | Derivados de dihidroquinolina como inhibidores de bromodominio | |
| ES2573706T3 (es) | Derivados de tetrahidroquinolinas como inhibidores de bromodominio | |
| ES2637595T3 (es) | Derivados de 7-(3,5-dimetil-4-isoxazolil)-8-(metiloxi)-1H-imidazo[4,5-c]quinolina | |
| ES2915658T3 (es) | Derivados de 1-acil-4-amino-1,2,3,4-tetrahidroquinolin-2,3-disustituida y su uso como inhibidores de bromodominio | |
| ES2449470T3 (es) | Derivados de tetrahidroquinolina y su uso farmacéutico | |
| ES2446358T3 (es) | Derivados de imidazo[4,5-c]quinolina como inhibidores de los bromodominios | |
| CN103889984B (zh) | 4-(8-甲氧基-1-(1-甲氧基丙烷-2-基)-2-(四氢-2H-吡喃-4-基)-1H-咪唑并[4,5-c]喹啉-7-基)-3,5-二甲基异噁唑及其作为溴结构域抑制剂的用途 | |
| ES2654931T3 (es) | Derivados de pirazolo[1,5-a]piridina y procedimientos de uso de los mismos | |
| ES2375735T3 (es) | Derivados de pirazolilaminopiridina útiles como inhibidores de quinasas. | |
| CN107709305A (zh) | 新型化合物 | |
| TW200800900A (en) | Novel pyridine derivatives and pyrimidine derivatives | |
| ES2831322T3 (es) | Compuestos de 2-oxo-1,2-dihidropiridin-3,5-dicarboxamida como inhibidores de bromodominios | |
| WO2015158310A1 (zh) | 一种酪氨酸激酶抑制剂及其用途 |